The increased sensitivity of PDOs derived from left-sided RAS/BRAF-WT tumors to panitumumab confirms our previous observations (16), reinforcing that tumor characteristics influencing targeted drug response are preserved in PDOs. This evidence concerns the gene BRAF and neoplasm.